Nanjing Shuangke Medicine Development Co., Ltd.

Main purpose: Using telmisartan tablets produced by Jiangsu Changjiang Pharmaceutical Co., Ltd. and provided by Nanjing Shuangke Pharmaceutical Development Co., Ltd. as the test preparation, according to the relevant provisions of bioequivalence studies, the absorption rate and degree of telmisartan tablets (trade name: Micardis®, reference preparation) produced by Boehringer Ingelheim Ellas A.E. were compared in healthy humans to investigate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation telmisartan tablets and the reference preparation telmisartan tablets (Micardis®) in healthy subjects.

Spironolactone tablets provided by Nanjing Shuangke Pharmaceutical Development Co., Ltd. were used as the test preparation. According to the relevant provisions of bioequivalence studies, the differences in absorption rate and absorption extent were compared with Spironolactone tablets (trade name: Aldactone®) produced by the original manufacturer Piramal Healthcare UK Limited in healthy adult subjects to investigate the bioequivalence of the two preparations in humans.

(1) To preliminarily explore the efficacy and safety of high, medium and low doses of doxifluridine for injection in the treatment of advanced breast cancer and gastric cancer; (2) To observe the in vivo time course of the drug after single and multiple doses of intravenous infusion of doxifluridine for injection in patients with breast cancer, gastric cancer, etc., estimate its pharmacokinetic parameters, and compare them with the pharmacokinetic parameters of patients after intravenous infusion of 5-FU, so as to provide guidance for clinical drug use.